LXRX Stock Price, Lexicon Pharmaceuticals Quote, Chart

Market Summary

USD1.60-0.01

Market Closed

-0.62%

LXRX Stock Price

View Fullscreen

LXRX RSI Chart

LXRX Valuation

Market Cap

396.4M

Price/Earnings (Trailing)

-2.24

Price/Sales (Trailing)

327.91

EV/EBITDA

-8.04

Price/Free Cashflow

-2.44

LXRX Price/Sales (Trailing)

LXRX Profitability

EBT Margin

-7258.73%

Return on Equity

-190.23%

Return on Assets

-77.2%

Free Cashflow Yield

-40.96%

LXRX Fundamentals

LXRX Revenue

Revenue (TTM)

1.2M

Rev. Growth (Yr)

2.4K%

Rev. Growth (Qtr)

333.33%

LXRX Earnings

Earnings (TTM)

-177.1M

Earnings Growth (Yr)

-63.17%

Earnings Growth (Qtr)

1.52%

Breaking Down LXRX Revenue

Last 7 days

-5.3%

Last 30 days

-28.8%

Last 90 days

-6.9%

Trailing 12 Months

-32.1%

How does LXRX drawdown profile look like?

LXRX Financial Health

Current Ratio

5.6

Debt/Equity

1.07

Debt/Cashflow

-1.63

LXRX Investor Care

Shares Dilution (1Y)

30.27%

Diluted EPS (TTM)

-0.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	419.0K	546.0K	1.2M
2022	0	306.0K	111.0K	116.0K
2021	18.1M	12.1M	6.2M	298.0K
2020	320.9M	320.3M	32.5M	24.0M
2019	47.1M	42.9M	330.4M	322.1M
2018	99.1M	100.8M	80.1M	63.2M
2017	88.8M	80.8M	80.8M	91.7M
2016	140.7M	160.4M	187.6M	83.3M
2015	24.4M	24.1M	24.2M	130.0M
2014	2.1M	2.6M	2.8M	22.9M
2013	1.1M	1.2M	1.0M	2.2M
2012	1.6M	1.2M	1.2M	1.1M
2011	3.9M	3.2M	2.8M	1.8M
2010	0	8.8M	6.8M	4.9M
2009	0	0	0	10.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lexicon Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2024	artal international s.c.a.	acquired	124,875,000	108	1,150,920	-
Feb 28, 2024	alexander kristen	acquired	-	-	29,243	vp, finance and accounting
Feb 28, 2024	kassler-taub kenneth b.	acquired	-	-	67,400	svp, regulatory & qa
Feb 28, 2024	mcdermott wendy	sold (taxes)	-58,753	2.62	-22,425	vp, human resources
Feb 28, 2024	main alan j	acquired	-	-	67,546	evp, innov & chem sciences
Feb 28, 2024	kassler-taub kenneth b.	sold (taxes)	-63,804	2.62	-24,353	svp, regulatory & qa
Feb 28, 2024	wade jeffrey l	acquired	-	-	97,564	president and cfo
Feb 28, 2024	mcdermott wendy	acquired	-	-	46,641	vp, human resources
Feb 28, 2024	coats lonnel	acquired	-	-	245,080	chief executive officer
Feb 28, 2024	granowitz craig b	sold (taxes)	-81,914	2.62	-31,265	svp, chief medical officer

Which funds bought or sold LXRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.78	-9,000	6,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	1,080	2,400	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	unchanged	-	9,431	26,018	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-46,689	-	-%
Apr 19, 2024	KWB Wealth	unchanged	-	35,357	97,536	0.01%
Apr 16, 2024	Berger Financial Group, Inc	unchanged	-	9,508	26,230	-%
Apr 15, 2024	Chemistry Wealth Management LLC	unchanged	-	10,440	28,800	0.01%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	new	-	170	170	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-6.56	2,173,740	9,149,970	-%

Are Funds Buying or Selling LXRX?

Are funds buying LXRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LXRX

No. of Funds

Unveiling Lexicon Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 13, 2024	invus, l.p.	15.8%	38,918,903	SC 13D/A
Feb 14, 2024	biotechnology value fund l p	5.1%	12,599,302	SC 13G/A
Jun 06, 2023	invus, l.p.	15.9%	38,918,903	SC 13D/A
Feb 14, 2023	biotechnology value fund l p	4.6%	8,686,034	SC 13G/A
Aug 01, 2022	invus, l.p.	21.2%	38,918,903	SC 13D/A
Feb 14, 2022	biotechnology value fund l p	5.1%	7,557,501	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Jan 21, 2021	invus, l.p.	27.5%	38,918,903	SC 13D/A
Jan 11, 2021	fmr llc	-	0	SC 13G/A
Jan 05, 2021	invus, l.p.	27.5%	38,918,903	SC 13D/A

Recent SEC filings of Lexicon Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Mar 26, 2024	ARS	ARS
Mar 26, 2024	DEF 14A	DEF 14A
Mar 26, 2024	DEFA14A	DEFA14A
Mar 25, 2024	10-K	Annual Report
Mar 25, 2024	S-3	S-3
Mar 13, 2024	4	Insider Trading
Mar 13, 2024	SC 13D/A	13D - Major Acquisition
Mar 12, 2024	8-K	Current Report
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	PRE 14A	PRE 14A

Peers (Alternatives to Lexicon Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Lexicon Pharmaceuticals Inc News

Latest updates

Lexicon Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	333.3%	702,000	162,000	317,000	28,000	39,000	35,000	14,000	23,000	234,000	216,500	199,000	6,634,000	9,163,000	7,999,000	8,727,000	294,448,000	9,682,000	9,216,000	17,071,000	6,966,000	13,798,000
Costs and Expenses	-4.7%	47,439,000	49,793,000	44,557,000	30,306,000	23,134,000	24,042,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	77,482,000	-23,134,000	-24,042,000	25,344,000	22,985,000	18,193,000	20,866,000	7,424,000	52,777,000	73,742,000	70,437,000	55,944,000	69,772,000	28,227,000	26,685,000	29,439,000	29,893,000	44,070,000
S&GA Expenses	1.2%	32,607,000	32,228,000	-	16,329,000	12,577,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-15.9%	14,762,000	17,558,000	14,541,000	13,977,000	10,557,000	13,356,000	16,498,000	15,682,000	10,257,000	12,609,000	992,000	40,147,000	57,301,000	55,181,000	40,606,000	26,659,000	12,637,000	12,022,000	12,307,000	13,763,000	26,477,000
EBITDA Margin	54.9%	-64.86	-143	-194	-728	-768	-281	-290	39.74	20.74	14.26	10.98	7.93	-	-	-	-	-	-	-	-	-
Interest Expenses	-39.3%	2,367,000	3,899,000	1,960,000	612,000	864,000	703,000	292,000	171,000	169,000	167,000	170,000	4,118,000	5,125,000	5,131,000	5,191,000	5,204,000	5,164,000	5,117,000	5,225,000	5,252,000	5,187,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-5,495,000	82,603,000	-	-	-51,138,000	220,072,000	-	-	-16,577,000	-27,396,000	-34,706,000
EBT Margin	54.8%	-72.59	-160	-209	-756	-790	-286	-294	39.54	20.26	13.62	10.25	7.22	-	-	-	-	-	-	-	-	-
Net Income	1.5%	-49,756,000	-50,525,000	-44,904,000	-30,494,000	-23,387,000	-24,587,000	-34,644,500	-23,122,000	-	-20,958,000	-38,800,500	82,603,000	-69,071,000	-	-51,138,000	226,086,000	-	-	-16,782,000	-27,396,000	-34,549,000
Net Income Margin	49.3%	-146	-289	-311	-878	-955	-345	-264	-18.87	-0.96	-0.65	0.39	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-21.2%	-50,548,000	-41,702,000	-38,256,000	-22,815,000	-19,443,000	-24,422,000	-22,851,000	-17,363,000	-22,827,000	-25,197,000	-34,293,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-17.0%	229	276	317	163	194	192	112	136	137	172	172	193	204	179	323	371	418	445	233	259	284
Current Assets	-21.0%	177	223	264	110	141	139	65.00	88.00	89.00	124	123	145	158	122	246	292	338	364	122	147	173
Cash Equivalents	6.4%	22.00	21.00	102	26.00	46.00	19.00	21.00	60.00	64.00	92.00	90.00	98.00	126	52.00	87.00	56.00	36.00	170	11.00	46.00	80.00
Inventory	13.4%	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	4.00	4.00	4.00	4.00	4.00	5.00	5.00
Net PPE	-6.9%	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	11.00	12.00	14.00	14.00	15.00	15.00	15.00	16.00
Goodwill	0%	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00	45.00
Liabilities	-0.5%	136	137	130	75.00	77.00	48.00	41.00	43.00	23.00	36.00	34.00	41.00	47.00	91.00	333	316	301	280	298	304	311
Current Liabilities	-2.2%	32.00	32.00	26.00	20.00	23.00	18.00	17.00	19.00	22.00	34.00	33.00	39.00	47.00	79.00	98.00	80.00	65.00	45.00	22.00	28.00	37.00
Long Term Debt	0.2%	100	99.00	99.00	49.00	49.00	24.00	24.00	23.00	-	-	-	-	-	12.00	235	234	234	234	244	244	244
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	12.00	12.00	12.00	12.00	9.00	10.00	11.00	11.00	11.00	1.00	1.00	1.00
LT Debt, Non Current	0.2%	100	99.00	99.00	49.00	49.00	24.00	24.00	23.00	-	-	-	-	-	12.00	235	234	234	234	244	244	244
Shareholder's Equity	-33.3%	93.00	140	186	88.00	117	144	71.00	93.00	114	137	137	153	156	88.00	-	55.00	117	165	-	-	-
Retained Earnings	-2.9%	-1,766	-1,717	-1,666	-1,621	-1,589	-1,559	-1,535	-1,511	-1,487	-1,462	-1,439	-1,420	-1,400	-1,394	-1,477	-1,408	-1,341	-1,290	-1,516	-1,493	-1,471
Additional Paid-In Capital	0.2%	1,863	1,859	1,856	1,713	1,709	1,706	1,609	1,606	1,609	1,606	1,584	1,581	1,561	1,487	1,471	1,467	1,462	1,459	1,455	1,451	1,448
Accumulated Depreciation	3.3%	5.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	64.00	63.00	61.00	62.00	62.00	62.00	62.00	60.00
Shares Outstanding	3.8%	221	213	197	189	166	175	149	149	146	146	144	143	-	107	-	-	-	-	-	-	-
Float	-	-	-	274	-	-	-	134	-	-	-	309	-	-	-	82.00	-	-	-	260	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-21.5%	-50,548	-41,619	-38,117	-31,613	-21,569	-19,439	-24,422	-23,421	-22,828	-17,150	-21,880	-25,159	-34,239	-40,378	-46,298	-22,054	-24,371	190,698	-26,900	-25,620	-27,128
Share Based Compensation	-17.6%	3,212	3,898	3,815	3,415	3,268	2,648	2,832	2,772	2,228	2,712	2,786	2,851	2,680	1,904	4,258	4,432	3,479	3,562	3,766	3,411	2,847
Cashflow From Investing	232.0%	51,898	-39,326	-74,608	12,093	24,174	-77,196	-13,648	-4,408	6,096	-400	14,138	-17,724	44,101	215,803	78,074	42,778	-109,398	-31,281	-7,450	-7,726	58,751
Cashflow From Financing	99.5%	-1.00	-210	188,995	-824	24,906	94,019	-	23,284	-11,321	19,781	-23.00	14,272	64,150	-210,117	-425	-1,244	-322	-320	-322	-1,262	-139
Buy Backs	-	-	-	-	824	-	-	-	864	-	-	-	2,675	-	-	103	923	-	-	-	941	-

LXRX Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Net product revenue	$ 1,110	$ 0	$ 0
Royalties and other revenue	94	139	298
Total revenues	1,204	139	298
Operating expenses:
Cost of sales	85	0	0
Research and development, including stock-based compensation of $5,139, $4,253 and $4,284 respectively	58,887	52,816	55,046
Selling, general and administrative, including stock-based compensation of $9,201, $7,267 and $6,293, respectively	113,982	48,083	32,342
Total operating expenses	172,954	100,899	87,388
Loss from operations	(171,750)	(100,760)	(87,090)
Other Expenses	(13,101)	(2,780)	(802)
Interest income and other, net	7,732	1,596	134
Net loss	$ (177,119)	$ (101,944)	$ (87,758)
Net loss per common share, basic (usd per share)	$ (0.80)	$ (0.62)	$ (0.60)
Net loss per common share, diluted (usd per share)	$ (0.80)	$ (0.62)	$ (0.60)
Shares used in computing net loss per common share, basic	221,130	165,733	145,652
Shares used in computing net loss per common share, diluted	221,130	165,733	145,652
Other comprehensive loss:
Unrealized gain (loss) on investments	$ 459	$ (418)	$ (4)
Comprehensive loss	$ (176,660)	$ (102,362)	$ (87,762)

LXRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 22,465	$ 46,345
Short-term investments	147,561	92,012
Accounts receivable, net	1,010	28
Inventory	381	0
Prepaid expenses and other current assets	5,130	2,481
Total current assets	176,547	140,866
Property and equipment, net of accumulated depreciation and amortization of $4,538 and $3,984, respectively	1,987	2,071
Goodwill	44,543	44,543
Operating lease right-of-use-assets	5,524	6,407
Other assets	828	412
Total assets	229,429	194,299
Current liabilities:
Accounts payable	14,389	10,395
Accrued liabilities	17,157	12,777
Total current liabilities	31,546	23,172
Long-term debt, net	99,508	48,579
Long-term operating lease liabilities	5,265	5,424
Total liabilities	136,319	77,175
Commitments and contingencies (Note 10)
Stockholders' Equity:
Preferred stock, $0.01 par value; 5,000,000 shares authorized; no shares issued and outstanding	$ 0	$ 0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, $0.001 par value; 300,000,000 shares authorized; 245,792,668 and 189,213,948 shares issued, respectively	$ 245	$ 189
Additional paid-in capital	1,862,558	1,709,144
Accumulated deficit	(1,766,839)	(1,589,720)
Accumulated other comprehensive income (loss)	31	(428)
Treasury stock, at cost, 867,973 and 488,205 shares, respectively	(2,885)	(2,061)
Total stockholders' equity	93,110	117,124
Total liabilities and stockholders’ equity	$ 229,429	$ 194,299

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

CEO	Mr. Lonnel Coats
WEBSITE	lexpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	135

Lexicon Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Lexicon Pharmaceuticals Inc? What does LXRX stand for in stocks?

LXRX is the stock ticker symbol of Lexicon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lexicon Pharmaceuticals Inc (LXRX)?

As of Tue Apr 23 2024, market cap of Lexicon Pharmaceuticals Inc is 396.44 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LXRX stock?

You can check LXRX's fair value in chart for subscribers.

What is the fair value of LXRX stock?

You can check LXRX's fair value in chart for subscribers. The fair value of Lexicon Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lexicon Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LXRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lexicon Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether LXRX is over valued or under valued. Whether Lexicon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Lexicon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LXRX.

What is Lexicon Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, LXRX's PE ratio (Price to Earnings) is -2.24 and Price to Sales (PS) ratio is 327.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LXRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lexicon Pharmaceuticals Inc's stock?

In the past 10 years, Lexicon Pharmaceuticals Inc has provided -0.17 (multiply by 100 for percentage) rate of return.